Clinical Trial Update: Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients [Phase 1, Phase 2]

View source ↗

Summary

A multicenter Phase 1/2 clinical trial is evaluating the combination of atezolizumab with the BEGEV chemotherapy regimen for relapsed or refractory Hodgkin lymp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Gemzar (gemcitabine)
• Navelbine (vinorelbine)
• Tecentriq (atezolizumab)
• Treanda (Bendamustine)

Snippet

Sponsor: Fondazione Italiana Linfomi - ETS | Conditions: Relapsed or Refractory Hodgkin's Lymphoma | Phase 1, Phase 2 | Status: RECRUITING